Publication

Dabrafenib plus trametinib versus anti-PD-1 monotherapy as adjuvant therapy in BRAF V600-mutant stage III melanoma after definitive surgery: a multicenter, retrospective cohort study

Bai, X
; 
Shaheen, A
; 
Grieco, C
; 
d'Arienzo, PD
; 
Mina, F
; 
Czapla, JA
; 
Lawless, AR
; 
Bongiovanni, E
; 
Santaniello, U
; 
Zappi, H
... show 10 more
Citations
Altmetric:
Abstract
Background: Both dabrafenib/trametinib (D/T) and anti-PD-1 monotherapy (PD-1) are approved adjuvant therapies for patients with stage III BRAF V600-mutant melanoma. However, there is still a lack of head-to-head comparative data. We aimed to describe efficacy and toxicity outcomes for these two standard therapies across melanoma centers.
Authors
Bai, X
Shaheen, A
Grieco, C
d'Arienzo, PD
Mina, F
Czapla, JA
Lawless, AR
Bongiovanni, E
Santaniello, U
Zappi, H
Dulak, D
Williamson, A
Lee, Rebecca
Gupta, Avinash
Li, C
Si, L
Ubaldi, M
Yamazaki, N
Ogata, D
Johnson, R
Park, BC
Jung, S
Madonna, G
Hochherz, J
Umeda, Y
Nakamura, Y
Gebhardt, C
Festino, L
Capone, M
Ascierto, PA
Johnson, DB
Lo, SN
Long, GV
Menzies, AM
Namikawa, K
Mandala, M
Guo, J
Lorigan, P
Najjar, YG
Haydon, A
Quaglino, P
Boland, GM
Sullivan, RJ
Furness, AJS
Plummer, R
Flaherty, KT
Affiliation
The Christie NHS Foundation Trust, Manchester, UK. Division of Cancer Sciences, University of Manchester and Christie NHS Foundation Trust, Manchester, UK.
Description
Date
2023
Publisher
Collections
All Christie Publications
Show all metadata
Keywords
Type
Article
Citation
Bai X, Shaheen A, Grieco C, d'Arienzo PD, Mina F, Czapla JA, et al. Dabrafenib plus trametinib versus anti-PD-1 monotherapy as adjuvant therapy in BRAF V600-mutant stage III melanoma after definitive surgery: a multicenter, retrospective cohort study. EClinicalMedicine. 2023 Nov;65:102290. PubMed PMID: 37965433. Pubmed Central PMCID: PMC10641479. Epub 2023/11/15. eng.
Journal Title
Journal ISSN
Volume Title
URI
http://hdl.handle.net/10541/626700
Embedded videos